Boardroom Alpha
10-K primary document
IVF · Annual Report (Form 10-K) · Filed June 2, 2026

Invo Fertility Inc10-K exhibit

ex10-104.htm

 

Exhibit 10.104

 

 

May 27, 2026

 

James Goren

JAG Multi Investments LLC

c/o Bredefeld & Assoc. PC

125 Maple Avenue, Suite C

Chester, New Jersey 07930

 

RE:Demand Notes and Warrants

 

Dear James

 

Reference is made to those certain demand notes dated October 21, October 28, November 10, December 13, December 29, 2022, and July 10, 2023 (the “Demand Notes”) issued by INVO Fertility, Inc. (f/k/a INVO Bioscience, Inc.; “INVO”) to JAG Multi Investments LLC (“JAG”). Under the Demand Notes, JAG loaned INVO a total of $600,000. The Demand Notes are currently in payment default and we are entering into this letter agreement (this “Agreement”) to cure such default. All capitalized terms used herein that are not defined shall have the meaning assigned to those terms in the Demand Notes.

 

By signing below, INVO and JAG agree to the following:

 

1.The maturity date of the Demand Notes is extended until December 31, 2026.

 

2.INVO shall pay $50,000 to JAG on May 15, 2026, and again on the fifteenth day of each subsequent month through November 15, 2026. In December 2026, INVO shall pay to JAG a balloon payment of any amount that remains outstanding.

 

3.Should INVO raise more than $3 million from the date hereof, INVO shall use ten percent (10%) of any amount raised in excess of $3 million to accelerate repayment of the Demand Notes (in chronological order).

 

4.Prior to making any payment on the Demand Notes, INVO shall provide JAG with at least five (5) days prior written notice of its intention to make such payment.

 

 
JAG Demand Note
Page 2 of 2

 

5.The Demand Notes are convertible into shares of INVO common stock, at JAG’s option, at price (the “Conversion Price”) equal to the closing price for INVO’s share of common stock as reflected on Nasdaq.com on the date hereof (the “Closing Price”).

 

6.INVO shall promptly issue to JAG a five-year warrant to purchase 150,000 shares of INVO common stock at a price per share (the “Exercise Price”) equal to the Closing Price, substantially in the form attached hereto as Exhibit A.

 

7.Should INVO raise funds at a price (the “Future Price”) that is below the Conversion Price and Exercise Price then in effect, INVO agrees to reset both the Conversion Price and the Exercise Price to equal the Future Price.

 

JAG hereby represents and warrants that it is an “accredited investor”, as such term is defined in Regulation D promulgated by the Commission under the 1933 Act, is experienced in investments and business matters, has made investments of a speculative nature and has purchased securities of United States publicly-owned companies in private placements in the past and, with its representatives, has such knowledge and experience in financial, tax and other business matters as to enable it to utilize the information made available by INVO to evaluate the merits and risks of and to make an informed investment decision with respect to the proposed purchase, which represents a speculative investment.

 

Should the terms of this Agreement conflict with the terms of previous Demand Note amendment letters, the terms of this Agreement will govern.

 

Sincerely,  AGREED AND ACCEPTED BY
    
INVO FERTILITY, INC.  JAG MULTI INVESTMENTS LLC
    
/s/ Steve Shum  /s/ James Goren
Steve Shum, CEO  James Goren, Managing Member

 

 
 

 

EXHIBIT A

 

Form of Warrant

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer